Navigation Links
PharmAthene Reports First Quarter 2008 Financial Results
Date:5/13/2008

ommence the first Phase I safety study in humans, which is expected to

be completed early next year.

Financial Results

PharmAthene received revenues of $5.8 million for the three months ended March 31, 2008 compared to $3.0 million for the same period in 2007. These revenues consist primarily of contract and grant funding from the U.S. government for the development of the Company's chemical nerve agent prophylaxis, Protexia(R).

PharmAthene's research and development expenses were $5.9 million and $3.1 million for the three months ended March 31, 2008 and 2007, respectively. These expenses resulted primarily from research and development activities related to the development of Valortim(TM) for protection against and treatment of inhalation anthrax, and the development of Protexia(R) for treatment of nerve agent poisoning. Research and development expense increased $2.8 million for the three months ended March 31, 2008 as compared to the same period in 2007, primarily as a result of increased process development and manufacturing activities for both Valortim(TM) and Protexia(R), and employee-related expenses including stock compensation expense.

General and administrative expenses for the Company were $4.7 million and $2.5 million respectively, for the three months ended March 31, 2008 and 2007. Expenses associated with general and administrative functions for the Company increased $2.2 million primarily due to increased employee costs, increased stock compensation expense and additional costs associated with the Company's compliance and legal functions.

PharmAthene's net loss for the first quarter of 2008 was $5.0 million or $0.23 per share.

As of March 31, 2008, available cash, cash equivalents and short term investments were $25.7 million, after giving effect to $20.0 million in restricted cash.

Conference Call Information

PharmAthene management will host a conference call to discuss the Company's f
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008
2. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
3. PharmAthene Reports Year-End 2007 Financial Results
4. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
5. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
6. PharmAthene to Delay Release of Full Year 2007 Financial Results
7. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
10. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
11. PharmAthene to Present at the BIO CEO & Investor Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... -- Cambrex Corporation (NYSE: CBM ) reports results ... Highlights , Second quarter sales increased 59% ... last year. , Second quarter EBITDA increased 86% to ... last year (see table at the end of this release). ... impact of foreign currency, to between 13% and 16% over ...
(Date:7/31/2014)... August 01, 2014 “2014 ... Polyurethane Resin Industry” is a professional and ... The report introduces Polyurethane Resin basic information, ... chain structure and industry overview. This research ... domestic market as well as global industry ...
(Date:7/31/2014)... is famous for a number of breakthroughs, which altered ... published a paper, which laid the foundation of computer ... algorithm. He next played a pivotal role in the ... German military codes, enabling the Allies to defeat the ... 1940,s he turned his attention to artificial intelligence and ...
(Date:7/31/2014)... COLORADO SPRINGS, Colo. , July 31, 2014 ... Seed Grant awardee today with $25,000 to fund ... the Foundation,s inception in 2011, the gift was ... 11 th Annual Meeting in ... physicians who specialize in neurointerventional approaches to neurovascular ...
Breaking Biology Technology:Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3
... long-awaited speaking faculty for the September Pharma ChemOutsourcing ... conference website reports Mark Alexay, President of Apaporis ... comprised of 100 speakers from pharmaceutical companies and ... the pipeline. The speaker list may be viewed ...
... Christine Lawless, MD, has accepted the position as ... continuing medical education (CME), beginning March 2, 2009. Recognized ... medicine cardiology, Dr. Lawless recently completed her clinical tenure ... where she was Associate Professor of Internal Medicine and ...
... Endpoints,NEW YORK, March 10 Intra-Cellular Therapies, Inc. today ... trial in patients with Sleep Maintenance Insomnia (SMI). ... wave sleep and decreased the duration of wake after ... prespecified primary and key secondary endpoints of the trial. ...
Cached Biology Technology:Pharma ChemOutsourcing Unveils 100 Pharma & Biotech Speaker Faculty for 2009 Conference September 14-16 in Long Branch, NJ 2Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise 2Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 2Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 3Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 4Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 5Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 6Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 7
(Date:7/31/2014)... found to be a key gene responsible for hearing in ... cells of the inner ear that contracts and expands rapidly ... phonograph horn, amplify sound waves to make hearing more sensitivity. ... advanced online edition of Molecular Biology and Evolution , ... independently evolved to play a critical role in the ultrasonic ...
(Date:7/31/2014)... By tracing nearly 3,000 genes to the earliest ... Florida scientists have created an extensive "Tree of ... next-generation DNA sequencing. , Among the study,s ... to small moths than to large ones, which ... The study also found that some insects once ...
(Date:7/31/2014)... studied 100 twin pairs have identified a gene mutation that ... six hours of sleep per night. The genetic variant ... sleep deprivation. , Results show that a participant with p.Tyr362His ... average nightly sleep duration of only five hours, which was ... slept for about six hours and five minutes per night. ...
Breaking Biology News(10 mins):UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Study of twins discovers gene mutation linked to short sleep duration 2
... A new technique for transplanting the ovaries of women ... cancer treatment was outlined to the 25th annual conference ... today (Monday 29 June). Dr. Pascal Piver, ... Limoges, France, described a new, two-step method of ovarian ...
... Shingu City, Japan--Deepsea Drilling Vessel CHIKYU has resumed IODP ... the Kii Peninsula of Japan. The scientific drilling expedition,s ... meters. Following sea floor surveys, the crew began fitting ... an upper section of the first borehole to be ...
... June 2009 Elsevier, the leading publisher of scientific, ... the highlights of its journal impact factor performance in ... factors (IF) increase from 2007 to 2008. According to ... journals took the #1 position in 51 categories (of ...
Cached Biology News:Ovarian transplantation: First baby is born after a new technique 2First riser-drilling research operations undertaken 2Elsevier announces 2008 journal impact factor highlights 2Elsevier announces 2008 journal impact factor highlights 3
The HQ505, 20 OptiGreen filter for the Molecular Imager FX is a band pass filter used for detection of Cy2 and FITC with 532 nm excitation....
... The APO-BRDU Kit is a 2-color staining ... cellular DNA to detect apoptotic cells by ... and reagents required for measuring apoptosis in ... for assessing reagent performance; washing, reaction and ...
... ApopTag Red In Situ Apoptosis Detection ... the indirect TUNEL method, utilizing an ... The kit provides indirect immunofluorescence staining ... using either fluorescence microscopy or flow ...
The sample holders for gels are used to hold gels in place in the multi-sample tray I, which is used with Molecular Imager FX imaging systems....
Biology Products: